Agilent Technologies, Inc.

A · NYSE

Agilent's CrossLab segment is becoming the quiet efficiency layer for regulated pharma labs: services, consumables, software, automation, and asset monitoring. The proof gate is whether CrossLab can keep growing while margin stays strong.

Follow Add to Watchlist Ask Question

NYSE A Agilent CrossLab Life Sciences Tools Pharmaceutical Labs

Latest ReportJun 5, 2026Agilent CrossLab Is Secretly Solving The Efficiency Crisis Facing Major Pharmaceutical LabsView report ->Total Reports2Published reportsView all ->Active Discussions0No visible comments yetView discussions ->Member WorkspaceLockedFinancials, timeline, comparisons, scorecard, and discussion require a paid login.View access ->

Admin-only preview

Valuation is limited to admins for now.

The valuation workbench is hidden from non-admin users until market-data licensing and trust disclosures are production-ready.